DTx in diabetes: A closer look at the market landscape [Infographic]

As of 2021, approximately 537 million adults are currently living with diabetes, across the world. This number is projected to rise to 643 million by 2030 and 783 million by 2045. Given the high level of support and treatment costs associated with this disease, the use of DTx in diabetes products have gained popularity in the last few years, as they not only reduce costs but also help in long-term symptom management.

The DTx in diabetes market has received record funding in the past year, crossing the USD 800 million mark for the first time ever. These hi-tech solutions help provide personalized medical interventions and therapies based on the patient’s vitals and previously recorded medical insights.

This form of treatment also acts as a form of preventive care for pre-diabetic patients, alerting them of their glucose levels and also monitoring their behavioral habits and cues. It also helps in treating the behavioral and mental health disorders which are often linked with chronic diseases such as diabetes, including depression, anxiety, panic attacks, etc.

Through our in-house healthcare market research expertise, we have compiled key insights for a holistic understanding of the current state of DTx in diabetes and its future growth prospects. Download this infographic to take a deep dive into:

• The major effects of diabetes on the body
• The benefits of using DTx in diabetes treatment
• The funding landscape of the DTx in diabetes market
• The highest funded companies in the DTx in diabetes market
• The regulatory landscape of DTx
• Stakeholders’ expectations from DTx in treating diabetes
• A future outlook of the DTx in diabetes market

For in-depth market research on DTx and to obtain customized insights for your organization, contact us today.